FIELD: biotechnology.
SUBSTANCE: present invention relates to use of bispecific antibodies in therapy of various cancerous diseases. Within the framework of the present invention, the possibility of using an antibody is disclosed, capable of binding programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) protein and containing a heavy chain sequence according to SEQ ID NO: 1 and a light chain sequence according to SEQ ID NO: 2, in therapy of this type of cancer, which is refractory to treatment with a programmed cell death 1 (PD-1) or PD-L1 inhibitor or recurs during or after treatment with a PD-1 or PD-L1 inhibitor. Present application also discloses dosage modes for administering the molecule of said antibody.
EFFECT: there are presented dosage regimens with introduction of bispecific antibodies against LAG-3/PD-L1.
17 cl, 11 dwg, 11 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
